High production of endothelin after foam sclerotherapy: A new pathogenetic hypothesis for neurological and visual disturbances after sclerotherapy

Phlebology

Volumn 26, Issue 5, 2011, Pages 203-208

  Frullini, Alessandro ^a   Felice, F ^b   Burchielli, S ^c   Di Stefano, R ^b  

^a Studio medico flebologico Dr Frullini ^*  (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Endothelin; Foam sclerotherapy; Neurological and retinal complications; Vasospasm

Indexed keywords

ENDOTHELIN 1; POLIDOCANOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN VASOSPASM; BRONCHOSPASM; CONTROLLED STUDY; FOAM; FOAM SCLEROTHERAPY; HYPOTHESIS; INTIMA; INTIMA IRRITATION; MEDIATOR RELEASE; MEDICAL LITERATURE; MIGRAINE; NEUROLOGICAL COMPLICATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; RETINA DISEASE; RETINA VASOSPASM; SCLEROTHERAPY; VASOSPASM; VISUAL DISORDER;

ANIMALS; BRAIN ISCHEMIA; CELL MOVEMENT; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; ENDOTHELINS; GASES; HUMANS; MIGRAINE WITH AURA; RATS; RETINA; SCLEROTHERAPY; VISION DISORDERS;

EID: 79960868830     PISSN: 02683555     EISSN: 14333031     Source Type: Journal    
DOI: 10.1258/phleb.2010.010029     Document Type: Article

References (38)

1. Cabrera Garrido JR, Cabrera Garcia Olmedo JR, Garcia Olmedo D. Nuevo metodo de esclerosis en las varices tronculares. Pathol Vasc 1993;1:55-72
2. Frullini A. Foam sclerotherapy: a review. Phlebolymphology 2003;40:125-9
3. Frullini A, Cavezzi A. Sclerosing foam in the treatment of varicose veins and teleangectasies: history and analysis of safety and complications. Dermatol Surg 2002;28:11-5
4. Morrison N. Ultrasound guided foam sclerotherapy: safety and efficacy. Phlebology 2009;24:239
5. Tessari L. Nouvelle technique d'obtention de la scléromousse. Phlébologie 2000;53:129
6. Morrison N. Studies on safety of foam sclerotherapy. In: Bergan J, Le Cheng V, eds. Foam Sclerotherapy: A Textbook. London: Royal Society of Medicine Press, 2008: 183-92
7. Morrison N. Foam sclerotherapy, how to improve results and reduce side effects. Phlébologie 2009;62:23-34
8. Forlee MV, Gouden M, Moore DJ, Shanik G. Stroke after varicose vein foam injection sclerotherapy. J Vasc Surg 2006;43:162-4
9. Bush RG, Derrick M, Manjoney D. Major neurological events following foam sclerotherapy. Phlebology 2008;23:189-92
10. Benigni JP. Sclérothérapie à la mousse et migraines à aura. Phlébologie 2005;4:323-4
11. Breu FX, Guggenbichler S, Wollmann JC. Second European Consensus Meeting of Foam Sclerotherapy. Duplex ultrasound and efficacy criteria in foam sclerotherapy from the 2nd European Consensus Meeting on Foam Sclerotherapy, 2006, Tegernsee, Germany. Vasa 2008;37:90-5
12. Gillet JL, Guedes JM, Guex JJ, et al. Etude Cesmous: effets secondaires et complications de la sclerotherapy à mousse de la grande et de la petite veinse saphéne. Etude prospective controlée incluant 1025 patients. Phlébologie 2009;4:29-39
13. Gillet JL. Troubles visuels et neurologiques après injection de mousse sclérosante. Phlébologie 2009;2:26-30
14. Guex JJ, Allaert FA, Gillet JL, Chleir F. Incidence des complications de la sclerotherapy: analyse d'u register prospectif multicentrique realize chez 22 phlébologues pendant 12 semaines (12,173 séances). Phlébologie 2005;2:189-95
15. Gillet JL, Guex JJ, Allaert FA, Chleir F. Incidence des complications de la sclerotherapy à la mousse: résultats de l'létude de la société Francaise de Phlébologie (SFP). Phlébologie 2005;4:349-51
16. Romero JR, Frey JL, Schwamm LH, et al. Cerebral ischemic events associated with 'Bubble Study' for identification of right to left shunts. Stroke 2009;40:2343-8
17. Tsivgoulis G, Heliopoulos I, Stamboulis E. Safety of TCD 'Bubble Study'. Stroke 2010;41:195
18. Iannaccone A, Letizia C, Pazzaglia S, Vingolo EM, Clemente G, Pannarale MR. Plasma endothelin-1 concentrations in patients with retinal vein occlusions. Br J Ophthalmol 1998;82:498-3
19. Ciulla TA, Pawlyk BS, Harris A, Oberoi A, Miller JW, Sandberg MA. Endothelin-1-mediated retinal artery vasospasm and the rabbit electroretinogram. J Ocul Pharmacol Ther 2000;4:393-8
20. Haufschild T, Prünte C, Messerli J, Flammer J. Erhöhter endothelin-1-plasmaspiegel bei retinalen Gefäßverschlüssen jüngerer Patienten. Klin Monatsbl Augenheilkd 2004;5:357-9
21. Takei K, Sato T, Nonoyama T, Miyauchi T, Goto K. Analysis of vasocontractile responses to endothelin-1 in rabbit retinal vessels using an ETA receptor antagonist and an ETB receptor agonist. Life Sci 1993;6:111-5
22. Kallela M, Färkkilä M, Saijonmaa O, Fyhrquist F. Endothelin in migraine patients. Cephalalgia 1998;6:329-32
23. Dreier JP, Kleeberg J, Petzold G, et al. Endothelin-1 potently induces Leão's cortical spreading depression in vivo in the rat. Brain 2002;1:102-12
24. Tzourio C, El Amrani M, Poirier O, Nicaud V, Bousser MG, Alpérovitch A. Association between migraine and endothelin type A receptor (ETA-231 A/G) gene polymorphism. Neurology 2001;56:1273-7
25. Färkkilä M, Palo J, Saijonmaa O, Fyhrquist F. Raised plasma endothelin during acute migraine attack. Cephalalgia 2005;6:383-4
26. Ziv I, Fleminger G, Djaldetti R, Achiron A, Melamed E, Sokolovsky M. Increased plasma endothelin-1 in acute ischemic stroke. Stroke 1992;23:1014-6
27. Mascia L, Fedorko L, Stewart DJ, Mohamed F, terBrugge K, Ranieri VM, Wallace MC, Pluta RM. Temporal relationship between endothelin-1 concentrations and cerebral vasospasm in patients with aneurysmal subarachnoid haemorrhage. Stroke 2001;32:1185-90
28. Shaller BJ. The role of endothelin in stroke: experimental data and underlying pathophysiology. Arch Med Sci 2006;3:146-58
29. Hasdai D, Holmes DR Jr, Garratt KN, Edwards WD, Lerman A. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circulation 1997;2:357-62
30. Yanagisawa M, Kurihawa H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5
31. Abraham D, Dashwood M. Endothelin-role in vascular disease. Rheumatology 2008;47:23-4
32. Letizia C, Cerci C, Subioli S, Scuro L. Clemente G increased plasma endothelin-1 after nicotine consumption in nonsmokers. Clin Chem 1997;43:2440-1
33. Loghin C, Sdringola S, Gould KL. Does coronary vasodilation after adenosine override endothelin-1-induced coronary vasoconstriction? Am J Physiol Heart Circ Physiol 2007;292:496-2
34. Di Stefano R, Frullini A, De Sanctis M, Mosca F. An endothelial model to test sclerosing agents in vitro. Vasomed 1999;2(Suppl 1):7
35. Wright D. Polidocanol does not remain on the surface of bubles free in the venous blood. Proceedings 2009 UIP World Meeting. Int Angiol 2009:39;4(Suppl 1):39
36. Raymond-Martimbeau P. transient adverse events positively associated with patent foramen ovale after ultrasound-guided foam sclerotherapy. Phlebology 2009;24:114-9
37. Lowell RC, Gloviczki P, Miller VM. In vitro evaluation of endothelial and smooth muscle function of primary varicose veins. J Vasc Surg 1992;5:679-86
38. Barber DA, Wang X, Gloviczki P, Miller VM. Characterization of endothelin receptors in human varicose veins. J Vasc Surg 1997;1:61-9